Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of TQ05105 in Participants With Mild Hepatic Impairment (Child-Pugh A), Moderate Hepatic Impairment (Child-Pugh B), and Healthy Subjects
Latest Information Update: 24 Mar 2026
At a glance
- Drugs Rovadicitinib (Primary)
- Indications Liver cirrhosis; Liver disorders; Myelofibrosis
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 24 Mar 2026 New trial record